Filtered By:
Drug: Melatonin
Countries: Iran Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments
CONCLUSION: Long-term usage of melatonin even after completion of adjuvant therapies in women with breast cancer decreased the levels of fatigue associated with the malignant condition and its treatments.THE TRIAL REGISTRY NAME AND URL, AND REGISTRATION NUMBER: Iranian Registry of Clinical Trials, https://en.irct.ir/trial/62267, IRCT20180426039421N3.PMID:37139718 | DOI:10.1177/15347354231168624
Source: Cancer Control - May 4, 2023 Category: Cancer & Oncology Authors: Abdolazim Sedighi Pashaki Fateme Sheida Leila Moaddab Shoar Tahereh Hashem Danial Fazilat-Panah Alireza Nemati Motehaver Ali Ghanbari Motlagh Safoora Nikzad Mojtaba Bakhtiari Leili Tapak Zahir Keshtpour Amlashi Seyed Alireza Javadinia Zahra Keshtpour Amla Source Type: research
Postnatal melatonin administration to stressed dams for ameliorating risk-taking behaviour in rat pups through maternal care improvement
CONCLUSION: It was concluded that prenatal restraint stress could impair stress responses and quality of maternal care, whereas postnatal melatonin administration potentially contributed to the normalization of stress reaction and anxiolysis.PMID:37114289 | DOI:10.1002/jdn.10265
Source: International Journal of Developmental Neuroscience - April 28, 2023 Category: Neuroscience Authors: Farzaneh Bagheri Iran Goudarzi Source Type: research
A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement
Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):494-499.ABSTRACTNo effective antiviral drugs and vaccines are available for the treatment of patients with severe coronavirus 2019 (COVID-19). Therefore, available, safe, and inexpensive drugs and supplements such as melatonin are among the proposed options for controlling inflammation. We did a randomized, single-blind study in Imam Khomeini Hospital between June 30, 2020, and August 5, 2020. Mild to moderate COVID-19 patients aged 25-65 years were eligible to enter the study based on chest CT scan, clinical symptoms, and physician diagnosis. The intervention group was presc...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 22, 2021 Category: Allergy & Immunology Authors: Zahra Alizadeh Nastaran Keyhanian Sara Ghaderkhani Simin Dashti-Khavidaki Raheleh Shokouhi Shoormasti Zahra Pourpak Source Type: research
